PLCB4 and urinary bladder cancer: Considering the following criteria: a) involvement of a protein in altered pathways following PFN1 down-regulation based on the functional annotation/pathway analysis results; b) the differential expression/excretion based on the secretome/proteome analysis and the gene expression data and c) availability of the antibodies; immunohistochemical analysis of bladder cancer tissue sections was further performed for Wnt5b, PLCb4, cAMP response element-binding protein1 (CREB1) and ANGPT1.